Filing Flows › Edwards Lifesciences (EW) › Q3 2026
Edwards Lifesciences (EW) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Edwards Lifesciences (EW) reported revenue of $1.7B for the third quarter 2026 (Q3 2026), +10% from a year earlier and -1% from the quarter before. Operating margin was 17.4%, net earnings $308M (17.9% of revenue).
Edwards Lifesciences, Q3 2026: revenue $1.7B (+10% year over year), operating margin 17.4%, net earnings $308M, operating cash flow $570M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7B | -1% | +10% |
| Gross profit | $1.3B | -0.2% | +11% |
| Operating profit | $299M | -42% | -3% |
| Net earnings | $308M | +27% | +6% |
| Operating cash flow | $570M | -13% | -0.6% |
| Free cash flow | $507M | -13% | -2% |
What changed
Revenue was $1.7B in Q3 2026, up 10% year over year and down 1% from the previous quarter. Transcatheter Aortic Valve Replacement was the largest line at 72% of revenue. Transcatheter Aortic Valve Replacement added $0.09B year over year (up 8%), 56% of the total change.
Gross margin was 78.5%, up 0.7 points from Q3 2025. Operating profit was $0.30B, a 17.4% margin (down 2.3 points year over year). Operating profit fell $0.01B even though revenue rose $0.16B versus Q3 2025, so costs grew faster than sales. Operating expenses grew 16% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+94%). Net earnings were $0.31B, up 6% year over year ($0.30B including minority interests, which bore $0.01B of losses). The effective tax rate was 17.0%.
Operating cash flow was $0.57B (down 1% year over year), 189% of net income including minority interests. Non-cash charges added back $0.04B of depreciation and amortization and $0.05B of share-based compensation. Working capital and other items added $0.18B. Capital expenditures of $0.06B left free cash flow of $0.51B.
Questions
What was Edwards Lifesciences' revenue in the third quarter 2026?
Edwards Lifesciences (EW) reported revenue of $1.7B for the third quarter 2026 (Q3 2026), +10% from a year earlier and -1% from the quarter before.
Was Edwards Lifesciences profitable in the third quarter 2026?
Operating profit was $299M (17.4% of revenue) and net earnings $308M.